Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.38 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.32 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007775 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11033302 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL308389 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10356239 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3862937 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11210752 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5559507 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Potassium Ion SCHEMBL9419061 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3899113 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Zinc Ion SCHEMBL1065443 | 0.96 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273493-A1 | AMORPHOUS TRISODIUM SACUBITRIL VALSARTAN AND A PROCESS FOR THE PREPARATION THEREOF | MYLAN LABORATORIES LIMITED (IN) | 2018-09-27 | — | — | US | claimed |
| US-9593124-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-03-14 | — | — | US | claimed |
| WO-2016125123-A1 | AMORPHOUS TRISODIUM SACUBITRIL VALSARTAN AND A PROCESS FOR THE PREPARATION THEREOF | MYLAN LABORATORIES LIMITED (IN) | 2016-08-11 | — | — | WO | claimed |
| EP-2995614-A1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | Rhodes Technologies Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| US-20150336972-A1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | NORAMCO, LLC | 2015-11-26 | — | — | US | claimed |
| US-9127014-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2015-09-08 | — | — | US | claimed |
| EP-2580201-A2 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | Rhodes Technologies (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154827-A2 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | RHODES TECHNOLOGIES (US) | 2011-12-15 | — | — | WO | claimed |
| US-10562866-B2 | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof | MYLAN LABORATORIES LIMITED (IN) | 2020-02-18 | — | — | US | disclosed |
| US-20180273493-A1 | AMORPHOUS TRISODIUM SACUBITRIL VALSARTAN AND A PROCESS FOR THE PREPARATION THEREOF | MYLAN LABORATORIES LIMITED (IN) | 2018-09-27 | — | — | US | disclosed |
| EP-2995614-B1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | RHODES TECH INC (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2580201-B1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | RHODES TECH (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9657030-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-05-23 | — | — | US | disclosed |
| US-9624232-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-04-18 | — | — | US | disclosed |
| US-20060094872-A1 | Process for the preparation of cephalosporin antibiotic | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2006-05-04 | — | — | US | disclosed |
| US-20060058281-A1 | Process for the preparation of cephalosporin antibiotic | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2006-03-16 | — | — | US | disclosed |
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| US-4379152-A | Cephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-04-05 | — | — | US | disclosed |
| US-RE29164-E | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-3981865-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JA) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336972-A1 | TRANSITION METAL-CATALYZED PROCESSES FOR THE PREPARATION OF N-ALLYL COMPOUNDS AND USE THEREOF | OPRK1, OPRM1, OPRD1 | PDE4A 690/4885CA4 1570/4885THRB 2096/4885 |
| US-20060094872-A1 | Process for the preparation of cephalosporin antibiotic | MRPL21, CYP4F11, TREH | PDE4A 451/4885CA4 617/4885THRB 3906/4885 |
| US-20180273493-A1 | AMORPHOUS TRISODIUM SACUBITRIL VALSARTAN AND A PROCESS FOR THE PREPARATION THEREOF | AGT, ACE, TTR | PDE4A 2165/4885CA4 953/4885THRB 2188/4885 |
| US-20060058281-A1 | Process for the preparation of cephalosporin antibiotic | CUL1, MRPL21, DCAF1 | PDE4A 1843/4885CA4 1030/4885THRB 3606/4885 |
| US-10562866-B2 | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof | AGT, ACE, TTR | PDE4A 2165/4885CA4 953/4885THRB 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.